Treatment of remains challenging, despite the availability ceftolozane-tazobactam. We report a treatment failure with ceftolozane-tazobactam salvage therapy for pneumonia complicated by lung abscess. Drug resistance, dose selection, and source control are possible contributing factors. Ceftolozane-tazobactam susceptibility testing should precede therapy and consideration should be given to dosing selection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028400 | PMC |
| http://dx.doi.org/10.1002/ccr3.1612 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differential frequency of persister cells in clinically derived isolates of Pseudomonas aeruginosa after exposure to cefiderocol and ceftolozane/tazobactam.
J Antimicrob Chemother
December 2024
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
Background: Bacterial persistence is a phenomenon whereby a subpopulation of bacteria survive high concentrations of an active antibiotic in the absence of phenotypic alterations. Persisters are associated with chronic and recurrent infections for pathogens including Pseudomonas aeruginosa. Understanding persister profiles of newer antibiotics such as cefiderocol and ceftolozane/tazobactam against P.
View Article and Find Full Text PDFClinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis.
J Antimicrob Chemother
August 2024
Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Objectives: To investigate clinical outcomes of patients with Pseudomonas endocarditis and identify factors associated with treatment failure.
Methods: Adult patients meeting definitive Duke's criteria for Pseudomonas endocarditis at 11 hospitals were identified between May 2000 and February 2024. Failure was defined as death or microbiological failure by day 42.
Efficacy and safety of antibiotics targeting Gram-negative bacteria in nosocomial pneumonia: a systematic review and Bayesian network meta-analysis.
Ann Intensive Care
April 2024
University of Angers, Inserm, CNRS, MINT, SFR ICAT, 49000, Angers, France.
Article Synopsis
- * No significant survival advantage was found among most beta-lactam antibiotics, but the combination of meropenem and aerosolized colistin showed a reduction in mortality compared to intravenous colistin alone.
- * Although ceftolozane/tazobactam showed potential superiority for microbiological cure, ceftazidime had a higher clinical failure rate compared to other treatments, and intravenous colistin was linked to more acute kidney failure in safety assessments.
Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study.
Ann Intern Med
May 2024
Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda; and Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland (J.R.S., A.Mishuk, C.Y.D., A.Mansera, B.J.S., M.W., C.Y., M.N., S.W., S.S.K.).
Background: The U.S. antibiotic market failure has threatened future innovation and supply.
View Article and Find Full Text PDFIntravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience.
Int J Antimicrob Agents
May 2024
Department of Infectious Diseases, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy.
Aim: To investigate the efficacy of intravenous (IV) fosfomycin as combination therapy for treatment of difficult-to-treat (DTT) acute and subacute infections with multi-drug-resistant (MDR) Gram-negative bacteria (GNB), and risk factors associated with 90-day mortality.
Methods: A retrospective, observational, monocentric study enrolled patients treated with IV fosfomycin in combination regimens (≥72 h) for proven DTT-MDR-GNB infection. Multi-variate regression analysis identified independent risk factors for 90-day mortality.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!